Figures computed from official regulatory filings — .
Analysttarget 15.5 USD (+1390%) · consensus 5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 17.92% · institutions 14.79% · short 6.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BioCardia, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
231 buys30 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Altman Petertrack record | Buy | $1K | conv 36 |
| Altman Petertrack record | Buy | $2K | conv 36 | SEC |
| Altman Petertrack record | Buy | $872 | conv 28 | SEC |
| Altman Petertrack record | Buy | $5K | conv 50 | SEC |
| Altman Petertrack record | Buy | $1.7K | conv 40 | SEC |
| Altman Petertrack record | Buy | $3.9K | conv 46 | SEC |
| Altman Petertrack record | Buy | $415 | conv 40 | SEC |
| Altman Petertrack record | Buy | $2.5K | conv 40 | SEC |
| Altman Petertrack record | Buy | $1.3K | conv 40 | SEC |
| Altman Petertrack record | Buy | $940 | conv 40 | SEC |
| Altman Petertrack record | Buy | $900 | conv 40 | SEC |
| Altman Petertrack record | Buy | $5.3K | conv 40 | SEC |
| Altman Petertrack record | Buy | $5.2K | conv 40 | SEC |
| Altman Petertrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Slosman Marvintrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| McClung Davidtrack record | Other | $28.7K | SEC |
| STERTZER SIMON Htrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Blank Andrew Scotttrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GILLIS EDWARD M | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GILLIS EDWARD M | Other | $21.4K | SEC |
| Facteau Bill | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Altman Petertrack record | Other | $67.7K | SEC |
| McClung Davidtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Allen Jim L. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MOYES JAY M | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |